Press Releases HUYABIO Validates Protective Mechanism for Antiarrhythmic Drug HBI-3000 in AF Patients, Paving the Way for a New Era in Atrial Fibrillation Treatment HUYABIO Presents Positive Phase 2 Data on HBI-8000 and Nivolumab Combination for Advanced Melanoma HUYABIO International Announces Initiation of HBI-3000 Phase 2 Trial HUYABIO International Announces Completion of HBI-3000 Phase 1 Trial and FDA Approval to Proceed With Dose Escalation in Phase 2 HUYABIO Announces the Exclusive License of the KRAS Inhibitor from Shanghai Jemincare Pharmaceutical HUYABIO International Receives Regulatory Approval for Hiyasta® Monotherapy of Peripheral T-Cell Lymphoma in Japan HUYABIO Announces the Exclusive License of the Wee1 Inhibitor from Shanghai Pharmaceuticals HUYABIO International Announces Initiation of Phase 2 Atrial Fibrillation Trial HUYABIO Announces FDA Clearance to Initiate a Phase 1 Trial of SHP2 Inhibitor in Patients with KRAS and EGFR Mutated Tumors HUYABIO International Launches Hiyasta as Monotherapy for Adult T-cell Leukemia/Lymphoma in Japan HUYABIO Announces First Patient Treated in a Pivotal Study of HBI-8000 Combined with Opdivo® (nivolumab) in Patients with Advanced Melanoma HUYABIO Files an Investigational New Drug Application with the FDA for the Novel SHP2 Inhibitor HBI-2376 HUYABIO Announces HBI-8000 Brand Name of Hiyasta™ HUYABIO International Receives Regulatory Approval for HBI-8000 Monotherapy of Adult T-cell Leukemia/Lymphoma in Japan HUYABIO International Submits HBI-8000 Monotherapy for Peripheral T-cell Lymphoma for Regulatory Approval in Japan HUYABIO International Announces Global Clinical Trial Collaboration with Bristol Myers Squibb in Melanoma HUYABIO International and Tianjin Institute of Pharmaceutical Research Joint Venture Submits Chinese New Drug Application for Efinaconazole as Jublia™ HUYA Bioscience International Presents Positive Data on HBI-8000 at Society for Immunotherapy of Cancer Meeting HUYA Bioscience International Submits HBI-8000 Monotherapy for Adult T-cell Leukemia/Lymphoma for Regulatory Approval in Japan HUYA Bioscience International Announces Orphan Drug Designation for HBI-8000 Monotherapy Adult T-cell Leukemia-Lymphoma ATL in Japan HUYA Bioscience International Licenses the Novel SHP2 Inhibitor HBI-2376 for Development in Oncology HUYA Bioscience International Announces the Successful Completion of Phase 1 Trial of HBI-3000 HUYA Bioscience International Appoints Meiji Seika Pharma as Exclusive Distributor For HBI-8000 in Japan and Other Asian Countries HUYA Bioscience International Expanded Oncology Pipeline Includes Combination with Checkpoint Inhibitor for Solid Tumors HUYA Bioscience International Establishes Strategic Partnership with Suzhou BioTOP HUYA Bioscience International and CAS Innovation and Investment Company Establish Strategic Collaboration HUYA Bioscience International Sponsors 12th Annual Scrip Awards ‘Best New Drug’ Category HUYA Bioscience International Dr. Mireille Gillings Named Pharma Executive of the Year at the BioPharma Industry Awards 2016 HUYA Bioscience International Celebrates 10 Years in China HUYA Bioscience International Announces Orphan Drug Designation for HBI-8000 in Japan HUYA Bioscience International Sponsors ‘Best New Drug’ Category at SCRIP Awards HUYA Bioscience International Expands into South Korea HUYA Bioscience International Announces a Strategic Alliance with the Korea Drug Development Fund HUYA Bioscience International Celebrates its 10th Anniversary HUYA Bioscience International and TechCode Gu’an Lifesciences Park Establish Strategic Collaboration HUYA Bioscience International Further Expands Executive Team HUYA Bioscience International Sponsors Japan Society of HTLV-1 Annual Meeting HUYA Bioscience International CEO, Mireille Gillings, Ph.D., Named As Gold Award Winner In 2015 American Business Awards HUYA Bioscience International Wins Bronze Stevie® Award In 2015 Asia-Pacific Stevie Awards HUYA Bioscience International Completes First Cohort In Phase 1 Clinical Trial Of HBI-8000 In Japan HUYA Bioscience International Announces Regulatory Approval Of Chidamide, The First Selective HDAC Inhibitor In China HUYA Bioscience International Is The First To Leverage Tripartite Cooperation HUYA Bioscience International Establishes Alliance With China Wuqing Development Area HUYA Bioscience International And TIPR Announce Joint Venture To Develop Medical Innovation For Global Markets HUYA Bioscience International Announces Partnership with Changzhou Center for Biotech Development HUYA Bioscience Announces Partnership With Shanghai Zhangjiang Biotech Pharmaceutical Base HUYA Bioscience Announces New Partnership With Tianjin Research Center Of Basic Medical Sciences HUYA Bioscience Announces New Partnership With A High Profile Pharmaceutical Lab At Shanghai’s Prestigious Fudan University HUYA Bioscience International Announces Strategic Partnership With The Tianjin Institute Of Pharmaceutical Research HUYA Bioscience International Builds Long-Term Relationship With Shenzhen Polytechnic School Of Applied Chemistry And Biotechnology HUYA Bioscience International And Tianjin International Joint Academy Of Biotechnology And Medicine Form Alliance HUYA Bioscience International Forms Alliance With Zhejiang Chinese Medical University Life Science College HUYA Bioscience International Engages In Partnership With Liaoning (Benxi) Bio-Pharmaceutical Industry Base HUYA Bioscience And Wuhan Biolake Form Alliance To Help Accelerate China’s Bio-Industry Development HUYA Bioscience And Quintiles Announce Partnership For Phase I Development Of New Cancer Therapy HUYA Bioscience Establishes Strategic Partnership With Sun Yat-Sen University’s School Of Pharmaceutical Sciences HUYA Bioscience International And China Medical City Forge Alliance To Help Develop China’s Pharmaceutical Industry HUYA Bioscience International Strengthens R&D Leadership In Traditional Chinese Medicine With The School Of Chinese Materia Medica, Beijing University Of Chinese Medicine HUYA Bioscience International Establishes Strategic Partnership With School Of Medicine And Pharmacy, Ocean University Of China Solvay Pharmaceuticals Announces Strategic Partnership With HUYA To Access New Drug Candidates From China HUYA Bioscience Announces Strategic Alliance With Abbott On Drug And Biomarker Development Candidates From China HUYA Bioscience Int’l Announces Collaboration Agreement With The Beijing Institute Of Materia Medica, Chinese Academy Of Medical Sciences And Peking Union Medical College HUYA Bioscience Announces Agreement To Provide Schering- Plough With Drug Development Candidates From China HUYA Bioscience Int’l Announces First Pre-IND Outcome For A Development Stage Compound Sourced From China – HBI-8000, Promising New Cancer Compound HUYA Bioscience Int’l Announces Clinical Trial Milestones In China For Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile HUYA Bioscience International Licenses Clinical Stage Anti-Arrhythmic Compound From The Shanghai Institute Of Materia Medica HUYA Bioscience International And Chipscreen Biosciences Initiate A Phase I Clinical Cancer Trial HUYA Bioscience Licenses Chidamide Cancer Compound from Chipscreen Biosciences Organon Partners With HUYA To Identify And Develop Chinese Biopharmaceuticals
